Hospital

RBX2660, a standardized, stabilized, novel microbiota-based live therapeutic, shows promise treating patients with recurrent Clostridium difficile infection.

Ibalizumab-uiyk (Trogarzo) is a CD4-directed post-attachment HIV-1 inhibitor.

Abemaciclib (Verzenio; Lilly) is the first addition to adjuvant endocrine therapy approved by the FDA in two decades.

Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.

Electronic, open loop, clinical decision support system helped to produce a 38% lower overall mortality rate among patients with pneumonia.

Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for early and advanced breast cancer, advanced stomach cancer, and gastroesophageal junction cancer.

Acalabrutinib (Calquence; AstraZeneca) provides efficacy while maintaining favorable tolerability for patients with chronic lymphocytic leukemia.

FDA seeks to reduce diversion of pharmaceutical products via sales by unlicensed distributers and tighten up the supply chain by vetting trading partners.

Heat waves, which are on the rise, appear to pose particular cardiovascular risk for Black populations and men, new study results show.

FDA approves label update for Cabenuva that makes the therapy’s oral lead-in with cabotegravir and rilpivirine tablets optional.

Larry Buie, PharmD, BCOP, FASHP, outgoing president of the Hematology/Oncology Pharmacy Association (HOPA), shares some details of HOPA’s upcoming 2022 annual conference in Boston and provides an overview of his term as HOPA’s president.

Investigators also identified that a polymerase inhibitor with a unique modification largely resists its removal from the RNA by the exonuclease.

Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications.

Leveraging automation capabilities and operational capacity at scale, they bridge gaps and mitigate the impact of disruptions.

Pluvicto is indicated for the treatment of adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who were previously administered other anticancer therapies.

Bevacizumab (Avastin) is a vascular endothelial growth factor inhibitor indicated several cancer types.

The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.

Analysis of the trial show that intensifying the chemotherapy regimen allowed for elimination of radiation in 90% of pediatric patients with T-cell acute lymphoblastic leukemia.

It is critical for pharmacists to inquire about the use of e-cigarette or vaping products in patients that present with certain symptoms.

Results of an excess-deaths analysis show that 18.2 million individuals have likely died as a result of the pandemic.

Sandostatin treats severe diarrhea and flushing associated with metastatic carcinoid tumors, as well as treatment of acromegaly.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the understanding of malignant lymphomas’ pathobiology and relationship with the immune system evolved during her clinical and investigational research into the subject.

Omnipod 5 allows patients with diabetes to receive 72 hours of continuous, automated insulin administration.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the field of hematopathology has changed over the last decade.

Professional assistance programs provide pathway for health care professionals to return to practice following treatment for substance use disorder.

Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.